ImmunityBio (IBRX) earnings, Nov 9, 2026: quarterly results
In brief
ImmunityBio reported on Nov 9, 2026. Earnings per share changed −157% year over year, 157.1% below the estimate; revenue +52%. The stock is now 30.5% below its 52-week high, +307.3% over 12 months. Next report: Mar 2, 2027.
EPS vs estimate−157.1%
EPS, YoY−157%
Revenue, YoY+52%
Gap · day— · —
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| Aug 4, 2026 | −5.5% | −2.8% |
Next-quarter estimates, ratings and the IBRX chart are in the terminal.
Open the terminalFAQ
When is ImmunityBio's next earnings report?
Mar 2, 2027. The date comes from daily data and is corrected if the company moves it.
Did ImmunityBio's earnings grow?
Earnings per share fell 157% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.